Home  /  Resource Library  /  Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open label, randomised, phase 2 trial

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open label, randomised, phase 2 trial

Results of a phase II study investigating venetoclax combined with ibrutinib for treatment of relapsed CLL. (Abstract only)